A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

a study on Uveitis

Eligibility: for people ages 18-75 (full criteria)
Location: at UCLA
Dates: study started September 2024
completion around February 2028
Principal Investigator: by Edmund Tsui, MD (ucla)

Edmund Tsui

Description

Summary

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Official Title

A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis

Keywords

Uveitis, Posterior, Uveitis, Intermediate, Uveitis, Posterior Uveitis, Intermediate Uveitis, Pars Planitis, Brepocitinib PO QD

Eligibility

You can join if…

Open to people ages 18-75

Adult subjects (18-75 years old)
Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
Active uveitic disease in at least 1 eye
Weight > 40 kg with a body mass index ≤ 40 kg/m2

You CAN'T join if...

Has confirmed or suspected current diagnosis of infectious uveitis History of or have:

Lymphoproliferative disorder
active malignancy
cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
thrombosis orand cerebrovascularardiovascular ischemic event disease within the last 12 months
a high risk for herpes zoster reactivation
active or recent infections

Locations

Clinical Trial Site accepting new patients
Los Angeles California 90095 United States
Clinical Trial Site accepting new patients
Irvine California 92697 United States
Clinical Trial Site accepting new patients
Beverly Hills California 90211 United States
Clinical Trial Site accepting new patients
La Jolla California 92093 United States
Clinical Trial Site accepting new patients
Los Angeles California 90033 United States
Clinical Trial Site accepting new patients
Sacramento California 92825 United States
Clinical Trial Site accepting new patients
Fullerton California 92835 United States

Lead Scientist at University of California Health

Edmund Tsui, MD (ucla)
Associate Professor-in-residence, Ophthalmology, Medicine. Authored (or co-authored) 87 research publications

Details

Status: accepting new patients
Start Date: September 2024
Completion Date: February 2028 (estimated)
Sponsor: Priovant Therapeutics, Inc.
Links: Related Info
ID: NCT06431373
Phase: Phase 3 Uveitis Research Study
Study Type: Interventional
Participants: Expecting 300 study participants
Last Updated: November 2024